. 2014 Aug 25;6:92. doi: 10.1186/1758-5996-6-92

Table 3.

Prevalence of MS with respect to drug combination

Drug combination (n)	MS (%)
Lamivudine/Zidovudine/Nevirapine^† (35)	6 (17.1%)
Lamivudine/Zidovudine/Efavirens^† (15)	5 (33.3%)
Lamivudine/Stavudine/Nevirapine^† (6)	3 (50%)
Lamivudine/Stavudine/Efavirens^† (6)	1 (16.7%)
Lopinavir/Ritonavir/ Lamivudine/Zidovudine ^♣ (17)	2 (11.8%)
Lopinavir/Ritonavir/Tenofovir/Lamivudine ^♣ (14)	0 (0%)
Lopinavir/Ritonavir/Tenofovir/Emtricitabine ^♣ (19)	3 (15.8%)

^† = First-line drug combination ^♣ = Second-line drug combination n = number.